Evidence map›Paper›PMID 40617903›Full record

ReviewMolecular biotechnology2026

Application Advances of Lentiviral Vectors: From Gene Therapy to Vaccine Development.

Enyue Fang, Guodan He, Yutong Chang, Qijia He, Pan Chen, Kongxin Hu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. p21 Knockdown as a Therapeutic Strategy for Focal Cartilage Injury Repair.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Enyue Fang *Institute of Health Inspection and Quarantine, Chinese Academy of Quality and Inspection & Testing, Beijing, 100176, China. dlu_fangenyue@163.com.ORCID http://orcid.org/0000-0003-0140-5731
Guodan He *Department of Clinical Laboratory, The Second People's Hospital of Guiyang, Guiyang, 550000, China.
Yutong ChangInstitute of Health Inspection and Quarantine, Chinese Academy of Quality and Inspection & Testing, Beijing, 100176, China.
Qijia HeInstitute of Health Inspection and Quarantine, Chinese Academy of Quality and Inspection & Testing, Beijing, 100176, China.
Pan ChenDepartment of Medical Laboratory Science, Bengbu Medical University, Bengbu, 233030, China.
Kongxin HuInstitute of Health Inspection and Quarantine, Chinese Academy of Quality and Inspection & Testing, Beijing, 100176, China.

Funding

Fundamental Research Funds of the Chinese Academy of Quality and Inspection & Testing 2023JK004
6 · The paper itself

Abstract

Since their development in the 1990s, the applications of lentiviral vectors have rapidly extended to the fields of gene and cancer therapy, as well as vaccine development, owing to their unique advantages of efficiently transducing both dividing and nondividing cells and achieving stable and long-term expression of genes. However, with their clinical application, potential safety issues have emerged, such as the possibility of insertional oncogenesis, immune reactions, and tumorigenesis, which have attracted widespread attention from the academic and clinical communities. In this review, we thoroughly explore the strategies used to optimize lentiviral vectors and assess their potential benefits and risks in different fields. We summarize the latest research on the use of lentiviral vectors, covering their development, classification, and applications in cancer therapy, treatment of genetic diseases, and vaccine development, as well as discussing important safety considerations. This review acts as an informative reference for academics and clinicians, providing insights into the potential future research directions and possible clinical applications of lentiviral vectors. We hope that this review will promote the continuous improvement of lentiviral vector technology and realize its full therapeutic potential in the treatment and prevention of diseases.

Indexed as

Genetic TherapyGenetic VectorsLentivirusVaccine DevelopmentAnimalsHumansNeoplasmsCell and gene therapyConditionally replicating lentiviral vectorLentiviral vectorNon-integrating lentiviral vectorSafetyVaccine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.